Cargando…

Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma

The mutant IDH1 inhibitor ivosidenib improves outcomes for patients with IDH1-mutated cholangiocarcinoma, but resistance inevitably develops. Mechanisms of resistance and strategies to overcome resistance are poorly understood. Here we describe two patients with IDH1 R132C-mutated metastatic cholang...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cleary, James M., Rouaisnel, Betty, Daina, Antoine, Raghavan, Srivatsan, Roller, Lauren A., Huffman, Brandon M., Singh, Harshabad, Wen, Patrick Y., Bardeesy, Nabeel, Zoete, Vincent, Wolpin, Brian M., Losman, Julie-Aurore
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9440204/ https://www.ncbi.nlm.nih.gov/pubmed/36056177 http://dx.doi.org/10.1038/s41698-022-00304-5

Ejemplares similares

Ivosidenib for IDH1 Mutant Cholangiocarcinoma: A Narrative Review
por: Sumbly, Vikram, et al.
Publicado: (2022)

IDH-Mutated AML: Beyond Enasidenib and Ivosidenib Monotherapy: Highlights From SOHO 2021
Publicado: (2022)

The IDH1 inhibitor ivosidenib improved seizures in a patient with drug-resistant epilepsy from IDH1 mutant oligodendroglioma
por: Vo, Anh Huan, et al.
Publicado: (2022)

Clinical Utility of Ivosidenib in the Treatment of IDH1-Mutant Cholangiocarcinoma: Evidence To Date
por: Uson Junior, Pedro Luiz Serrano, et al.
Publicado: (2023)

Ivosidenib: IDH1 Inhibitor for the Treatment of Acute Myeloid Leukemia
por: Merchant, Shelby L., et al.
Publicado: (2019)

Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience
por: Rimini, Margherita, et al.
Publicado: (2023)

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers
por: Popovici-Muller, Janeta, et al.
Publicado: (2018)

Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial
por: Zhu, Andrew X., et al.
Publicado: (2021)

P724: UPDATED SUBSTUDY RESULTS FOR IVOSIDENIB IN IDH1-MUTANT RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROME
por: Dinardo, Courtney, et al.
Publicado: (2023)

Ivosidenib, an IDH1 inhibitor, in a patient with recurrent, IDH1-mutant glioblastoma: a case report from a Phase I study
por: Tejera, Dalissa, et al.
Publicado: (2020)

Population pharmacokinetic and exposure‐response analyses of ivosidenib in patients with IDH1‐mutant advanced hematologic malignancies
por: Jiang, Xuemin, et al.
Publicado: (2021)

IDH1 and IDH2 mutations in lung adenocarcinomas: Evidences of subclonal evolution
por: Rodriguez, Erika F., et al.
Publicado: (2020)

Consequences of IDH1/2 Mutations in Gliomas and an Assessment of Inhibitors Targeting Mutated IDH Proteins
por: Kaminska, Bozena, et al.
Publicado: (2019)

Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial
por: Mellinghoff, Ingo K., et al.
Publicado: (2023)

IDH Mutations in Chondrosarcoma: Case Closed or Not?
por: Venneker, Sanne, et al.
Publicado: (2023)

Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors
por: Fan, Bin, et al.
Publicado: (2019)

Mutant IDH1 is required for IDH1 mutated tumor cell growth
por: Jin, Genglin, et al.
Publicado: (2012)

IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression
por: DiNardo, Courtney D, et al.
Publicado: (2015)

IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives
por: Mondesir, Johanna, et al.
Publicado: (2016)

Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL
por: Simonin, Mathieu, et al.
Publicado: (2021)

Concurrent IDH1 and IDH2 mutations in glioblastoma: A case report
por: Haider, Ali S., et al.
Publicado: (2023)

Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance
por: Lyu, Junhua, et al.
Publicado: (2023)

Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH Mutations in Glioblastoma
por: Krell, Daniel, et al.
Publicado: (2011)

Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations
por: Intlekofer, Andrew M., et al.
Publicado: (2018)

Estimation of the occurrence rates of IDH1 and IDH2 mutations in gliomas and the reconsideration of IDH-wildtype anaplastic astrocytomas: an institutional experience
por: Cho, Uiju, et al.
Publicado: (2021)

The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas
por: Wang, Hao-Yuan, et al.
Publicado: (2016)

Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm
por: Issa, Ghayas C., et al.
Publicado: (2021)

Frequency and Prognostic Value of IDH Mutations in Korean Patients With Cholangiocarcinoma
por: Kim, Nah Ihm, et al.
Publicado: (2020)

Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma
por: Rimini, Margherita, et al.
Publicado: (2022)

Mismatch repair protein mutations in isocitrate dehydrogenase (IDH)-mutant astrocytoma and IDH-wild-type glioblastoma
por: Richardson, Timothy E, et al.
Publicado: (2023)

IDH1/IDH2 but Not TP53 Mutations Predict Prognosis in Bulgarian Glioblastoma Patients
por: Stancheva, Gergana, et al.
Publicado: (2014)

Isocitrate Dehydrogenase IDH1 and IDH2 Mutations in Human Cancer: Prognostic Implications for Gliomas
por: Murugan, A. K., et al.
Publicado: (2022)

Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations
por: Tesileanu, C. Mircea S., et al.
Publicado: (2021)

Mutation Analysis of IDH1 in Paired Gliomas Revealed IDH1 Mutation Was Not Associated with Malignant Progression but Predicted Longer Survival
por: Yao, Yu, et al.
Publicado: (2013)

The prognostic IDH1(R132) mutation is associated with reduced NADP(+)-dependent IDH activity in glioblastoma
por: Bleeker, Fonnet E., et al.
Publicado: (2010)

Novel Multiplex Bead-Based Assay for Detection of IDH1 and IDH2 Mutations in Myeloid Malignancies
por: Shivarov, Velizar, et al.
Publicado: (2013)

CLINICAL AND BIOLOGICAL IMPLICATIONS OF ANCESTRAL AND NON-ANCESTRAL IDH1 AND IDH2 MUTATIONS IN MYELOID NEOPLASMS
por: Molenaar, Remco J., et al.
Publicado: (2015)

Analysis of ALK, IDH1, IDH2 and MMP8 somatic mutations in differentiated thyroid cancers
por: Murugan, Avaniyapuram Kannan, et al.
Publicado: (2021)

Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia: Emerging Options and Pending Questions
por: Wouters, Bas J.
Publicado: (2021)

IDH1 mutations in a Brazilian series of Glioblastoma
por: Uno, Miyuki, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_jsubg5is696qgqrbu4q236e6bf